Low Dose Treatment of Ribavirin in Combination With PEG-IFN Alfa-2b [Peginterferon alfa-2b] in CHC [chronic hepatitis C] Patients With genotype1 High Viral Load and Low Body Weight.

Trial Profile

Low Dose Treatment of Ribavirin in Combination With PEG-IFN Alfa-2b [Peginterferon alfa-2b] in CHC [chronic hepatitis C] Patients With genotype1 High Viral Load and Low Body Weight.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 13 Jan 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 13 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top